Literature DB >> 29610200

EfrEF and the Transcription Regulator ChlR Are Required for Chlorhexidine Stress Response in Enterococcus faecalis V583.

Farry J Li1, Kelli L Palmer2.   

Abstract

Enterococcus faecalis is an opportunistic pathogen and leading cause of health care-associated infections. Daily chlorhexidine gluconate (CHG) bathing of patients is generally regarded as an effective strategy to reduce the occurrence of health care-associated infections. It is likely that E. faecalis is frequently exposed to inhibitory and subinhibitory concentrations of CHG in clinical settings. The goal of this study was to investigate how the vancomycin-resistant strain E. faecalis V583 transcriptionally responds to and tolerates stress from CHG. We used transcriptome (microarray) analysis to identify genes upregulated by E. faecalis V583 in response to CHG. The genes efrE (EF2226) and efrF (EF2227), encoding a heterodimeric ABC transport system, were the most highly upregulated genes. efrEF expression was induced by CHG at concentrations several 2-fold dilutions below the MIC. Deletion of efrEF increased E. faecalis V583 susceptibility to CHG. We found that ChlR, a MerR-like regulator encoded by a sequence upstream of efrEF, mediated the CHG-dependent upregulation of efrEF, and deletion of chlR also increased chlorhexidine susceptibility. Overall, our study gives insight into E. faecalis stress responses to a commonly used antiseptic.
Copyright © 2018 Li and Palmer.

Entities:  

Keywords:  Enterococcus; chlorhexidine

Mesh:

Substances:

Year:  2018        PMID: 29610200      PMCID: PMC5971576          DOI: 10.1128/AAC.00267-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


INTRODUCTION

Enterococci are Gram-positive bacteria and colonizers of the gastrointestinal tracts of humans and animals. Enterococcus faecalis, an opportunistic pathogen, is one of the leading causes of health care-associated infections, including bloodstream infections, surgical wound infections, and urinary tract infections (1). The intrinsic antibiotic resistance of E. faecalis combined with the horizontal acquisition of antibiotic resistance genes often complicates treatment of these infections (2). Vancomycin-resistant enterococci (VRE) are particularly of concern. Chlorhexidine is a bisbiguanide disinfectant and antiseptic with broad-spectrum antimicrobial efficiency against bacteria. Chlorhexidine gluconate (CHG), a chlorhexidine salt solution, is used for infection control, including whole-body rinsing of patients in intensive care units (ICUs), oral cleansing, and surgical hand washes. The mechanism of action and efficacy of chlorhexidine against bacteria have been studied for decades (3). It is generally postulated that the antimicrobial activity of chlorhexidine stems from its cationic nature. Chlorhexidine attaches to the negatively charged cell envelope, resulting in breakage of the outer leaflet. High concentrations of chlorhexidine severely compromise the cytoplasmic membrane, leading to cell lysis. At lower concentrations, near the MIC, chlorhexidine distorts the cell walls of Gram-positive and Gram-negative bacteria, leading to morphological changes in the cell surface (4). Uptake of chlorhexidine into the cytoplasm causes precipitation of the cytoplasmic components and inhibits ATPase activity (5, 6). Daily CHG bathing of ICU patients is used to control VRE and other nosocomial infections (7–9). CHG is typically detectable on patients' skin for 24 h postbath (10). However, VRE recover to the prebath density on patients' bodies in less than 24 h (10). This finding indicates that VRE are frequently exposed to inhibitory and subinhibitory CHG concentrations as a result of CHG bathing. Recent E. faecalis isolates from an ICU demonstrated a high prevalence of reduced chlorhexidine susceptibility (11). It is conceivable that extensive use of CHG bathing could select for strains with reduced chlorhexidine susceptibilities. It is currently not well understood how VRE respond to and tolerate stress from subinhibitory concentrations of CHG. By using microarray analysis, we found that gene expression in E. faecalis V583 is altered after CHG exposure. Of particular interest is that EF2226 and EF2227, which encode the heterodimeric ATP-binding cassette (ABC) transporter EfrEF (12), are the most upregulated genes in E. faecalis V583 upon exposure to CHG. By deletion analysis, we show that efrEF expression confers protection from CHG. Further, EF2225 (referred to as chlR here), a putative MerR family transcription regulator encoded by a sequence upstream of efrEF, mediates the upregulation of efrEF in response to CHG exposure.

RESULTS

E. faecalis V583 growth kinetics after H-CHG exposure.

E. faecalis V583 is a VanB-type vancomycin-resistant bloodstream infection isolate and model strain for E. faecalis studies (13, 14). The broth microdilution MIC of the commercially available Hibiclens CHG product (H-CHG) for E. faecalis V583 is 9.8 μg/ml, which is within the lowest range of CHG residual concentrations detected on patients' bodies (0 to 18.75 μg/ml) (10). We assessed the growth of E. faecalis V583 in response to different concentrations of H-CHG by spiking H-CHG into cultures in exponential phase (Fig. 1). We used the H-CHG MIC obtained by broth microdilution as a reference for the amount of H-CHG spiked into the cultures. V583 stops growing after exposure to 1× MIC H-CHG, but cells remain viable (Fig. 1a and b). V583 is initially growth inhibited but recovers to normal growth after exposure to 1/2× MIC H-CHG (Fig. 1a). After 20 h of incubation, the optical density at 600 nm (OD600) of cultures exposed to 1× MIC H-CHG was identical (OD600, ∼1.8) to that of untreated control cultures.
FIG 1

Growth curves. (a) The optical density at 600 nm (OD600) is shown on the y axis. Mid-exponential-phase E. faecalis V583 cultures (OD600, 0.4 to 0.5) were split into fresh, prewarmed medium to achieve different H-CHG concentrations (indicated with the arrow). For all experiments, 1× MIC is the broth microdilution MIC of E. faecalis V583. The time point at which RNA was harvested is also indicated. (b) Viable cell counts (number of CFU per milliliter) for 1× MIC-treated cultures and control cultures are shown. For this curve, the time at which cultures were split is set to 0 h. For both panels, error bars indicate standard deviations from 3 independent experiments.

Growth curves. (a) The optical density at 600 nm (OD600) is shown on the y axis. Mid-exponential-phase E. faecalis V583 cultures (OD600, 0.4 to 0.5) were split into fresh, prewarmed medium to achieve different H-CHG concentrations (indicated with the arrow). For all experiments, 1× MIC is the broth microdilution MIC of E. faecalis V583. The time point at which RNA was harvested is also indicated. (b) Viable cell counts (number of CFU per milliliter) for 1× MIC-treated cultures and control cultures are shown. For this curve, the time at which cultures were split is set to 0 h. For both panels, error bars indicate standard deviations from 3 independent experiments.

efrE and efrF are highly upregulated in response to H-CHG.

We used custom Affymetrix GeneChips with probes targeting E. faecalis V583 open reading frames (ORFs) (15) to assess the transcriptional response of V583 to H-CHG exposure. Across two independent experimental trials, exposure to 1× MIC H-CHG for 15 min resulted in the ≥4-fold upregulation of 75 genes compared to their expression levels in untreated cells (see Data Set S1 in the supplemental material). Of the 75 genes, 39 (52%) were predicted by the PSORTb (version 3.0) program (16) to encode membrane proteins (Data Set S1). In comparison, only 28.4% of the V583 proteome (884 of 3,112 proteins) is predicted to be membrane proteins (17). This is a significant enrichment for membrane proteins in the H-CHG stress response (χ2 test [degrees of freedom = 1, n = 3,187] = 18.685, P < 0.0001). Of the genes upregulated in response to H-CHG, efrE and efrF stood out with 286- and 326-fold upregulation, respectively. Semiquantitative reverse transcriptase PCR (RT-PCR) (Fig. S1) analyses confirmed the microarray results for these two genes, and quantitative RT-PCR (Fig. 2) confirmed the upregulation of efrF in the presence of H-CHG. We also assessed efrEF expression in the vancomycin-susceptible E. faecalis strain OG1RF, which we determined has the same broth microdilution H-CHG MIC (9.8 μg/ml) as E. faecalis V583. In the presence of H-CHG, the efrEF orthologs OG1RF_11766 and OG1RF_11767 are upregulated (Fig. 2 and S2).
FIG 2

Quantitative RT-PCR confirms H-CHG-dependent upregulation of efrF. Primers were designed to amplify ∼600-bp internal regions of efrF. RNA was harvested from E. faecalis V583 after 15 min of exposure to no CHG, 1/2× MIC H-CHG, or 1× MIC H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.

Quantitative RT-PCR confirms H-CHG-dependent upregulation of efrF. Primers were designed to amplify ∼600-bp internal regions of efrF. RNA was harvested from E. faecalis V583 after 15 min of exposure to no CHG, 1/2× MIC H-CHG, or 1× MIC H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05; **, P < 0.005; ***, P < 0.0005. ABC transporters typically consist of two subunits which function as homo- or heterodimers. A previous study purified EfrE and EfrF and determined that the proteins formed a heterodimer (12). It is therefore likely that efrE and efrF are cotranscribed and coregulated. To test this, RT-PCR was performed using RNA isolated from E. faecalis V583 grown in the presence of H-CHG. Primers were designed to amplify the 52-bp intergenic region between efrE and efrF, along with parts of the efrE and efrF coding regions. The results demonstrate that a transcript containing efrE and efrF is present in E. faecalis V583 (Fig. S2).

Deletion of efrEF increases H-CHG susceptibility.

To investigate how efrE and efrF impact H-CHG susceptibility in E. faecalis, we constructed an efrEF deletion mutant. Growth on brain heart infusion (BHI) medium was not affected when efrE and efrF were deleted (Fig. 3a). However, the deletion mutant was more susceptible to H-CHG than the wild-type strain in broth microdilution assays (MIC, 2.4 μg/ml H-CHG) and in agar plate assays (Fig. 3a). We complemented the ΔefrEF mutant by expressing efrEF from its native promoter on a multicopy plasmid. Complementation restored H-CHG susceptibility to wild-type levels (Fig. 3a).
FIG 3

efrEF and chlR deletion mutants are more susceptible to H-CHG. Overnight cultures were adjusted to an OD600 of ∼0.3 and serially diluted in 10-fold dilutions. Ten microliters of each dilution (from 10−1 to 10−6, from left to right in each image) was spotted on BHI agar supplemented with different concentrations of H-CHG. The images are representative of those from three independent trials. The results of experiments assessing the contributions of efrEF (a) and chlR (b) to chlorhexidine susceptibility are shown.

efrEF and chlR deletion mutants are more susceptible to H-CHG. Overnight cultures were adjusted to an OD600 of ∼0.3 and serially diluted in 10-fold dilutions. Ten microliters of each dilution (from 10−1 to 10−6, from left to right in each image) was spotted on BHI agar supplemented with different concentrations of H-CHG. The images are representative of those from three independent trials. The results of experiments assessing the contributions of efrEF (a) and chlR (b) to chlorhexidine susceptibility are shown.

ChlR, a MerR family regulator, mediates efrEF upregulation in response to H-CHG.

We were interested in how efrE and efrF are regulated. NCBI Conserved Domains analysis assigns EF2225 to the MerR-like family of transcription regulators. EF2225 is encoded by a sequence upstream of efrEF and is divergently transcribed. The layout of EF2225 and efrEF is representative of that of a MerR regulon (18, 19). We refer to EF2225 as chlR here. To investigate if ChlR regulates efrEF expression, a ΔchlR strain was constructed. The ΔchlR strain was complemented in trans by cloning the complete chlR gene and putative promoter into a multicopy vector. The ΔchlR mutant strain showed increased susceptibility to H-CHG (Fig. 3b), and its broth microdilution H-CHG MIC (4.9 μg/ml) was half that of the wild-type strain. H-CHG susceptibility was restored to the wild-type level in the complemented strain (Fig. 3b). To further substantiate the relationship between ChlR and efrEF, efrEF expression was assessed in the ΔchlR and complemented strains by quantitative reverse transcriptase PCR (qRT-PCR). Upon 15 min of exposure to 1/2× MIC H-CHG, the transcription levels of efrE and efrF in the ΔchlR mutant remained the same regardless of the presence of H-CHG, whereas H-CHG induced efrE and efrF expression in the chlR complemented strain (Fig. 4). This result demonstrates that ChlR is required for the upregulation of efrEF in response to H-CHG.
FIG 4

chlR is required for H-CHG-dependent upregulation of efrF. Quantitative RT-PCR was used to investigate efrF expression in cultures of wild-type strain V583, the ΔchlR mutant, the ΔchlR mutant with the empty complementation vector pCAT28, and the complemented ΔchlR strain (ΔchlR/pFL102) after 15 min of exposure to 1/2× MIC H-CHG or no H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05.

chlR is required for H-CHG-dependent upregulation of efrF. Quantitative RT-PCR was used to investigate efrF expression in cultures of wild-type strain V583, the ΔchlR mutant, the ΔchlR mutant with the empty complementation vector pCAT28, and the complemented ΔchlR strain (ΔchlR/pFL102) after 15 min of exposure to 1/2× MIC H-CHG or no H-CHG. The gyrase B (gyrB) gene was amplified as a control. *, P < 0.05. To investigate the efrEF promoter, primer extension was used to find the transcription start site (TSS) of efrE. Primer extension identified two transcription start sites. Under standard culture conditions in BHI broth, we identified a TSS at −78 bp upstream of the efrE ORF. When cells were exposed to H-CHG, an additional TSS was detected at −33 bp upstream of the efrE ORF; its corresponding promoter is designated P here. On the basis of this evidence, we propose that the efrEF operon has two promoters. One promoter, corresponding to the TSS at −78 bp upstream of the efrE ORF, is constitutive and is responsible for basal transcription of efrEF. P is a ChlR-dependent promoter (Fig. 5).
FIG 5

Organization of chlR-efrE intergenic region. The organization of the chlR and efrEF genes is shown (the arrows are not drawn to scale). Transcription start sites (TSS) were detected 33 and 78 bp upstream of the efrE ORF. Consensus −35 and near-consensus −10 housekeeping sigma factor promoter sequences upstream of the H-CHG-responsive efrE promoter (P) are shown in bold. Putative ChlR binding motifs are underlined. The predicted promoter for the −78-bp TSS is not shown for clarity.

Organization of chlR-efrE intergenic region. The organization of the chlR and efrEF genes is shown (the arrows are not drawn to scale). Transcription start sites (TSS) were detected 33 and 78 bp upstream of the efrE ORF. Consensus −35 and near-consensus −10 housekeeping sigma factor promoter sequences upstream of the H-CHG-responsive efrE promoter (P) are shown in bold. Putative ChlR binding motifs are underlined. The predicted promoter for the −78-bp TSS is not shown for clarity. On the basis of existing knowledge of MerR family regulators (18), the chlR promoter is predicted to be oriented opposite to P. We obtained inconsistent results across multiple primer extension trials for the chlR TSS. The presumptive chlR promoter is designated P here.

H-CHG treatment induces ChlR to activate the efrEF promoter.

In our microarray trials, the expression of chlR was not affected by H-CHG (fold change = 0.3; P = 0.57). This evidence indicates that H-CHG may directly or indirectly trigger the activation of ChlR. We performed β-galactosidase assays to assess the responses of the efrEF promoter P to H-CHG. Promoter reporter strains were spotted on agar plates supplemented with 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) and different concentrations of H-CHG (Fig. 6). As expected, the control strain lacking a promoter for lacZ, E. faecalis V583/pPB101 (strain FL101), displayed no detectable β-galactosidase activity in the presence or absence of H-CHG (Fig. 6a). For cultures without H-CHG, P promoter activity was not detected. Subinhibitory concentrations of H-CHG elicited increases in P promoter activity (Fig. 6a). These results demonstrate that H-CHG is required to stimulate efrEF promoter activity and that H-CHG concentrations several 2-fold dilutions below the MIC still elicit this response. Conversely, P induction by H-CHG was absent in V583 ΔchlR (Fig. 6a). We conclude that ChlR is required for activation of the efrEF promoter upon H-CHG exposure.
FIG 6

β-Galactosidase assays. Cultures were spotted on BHI agar plates supplemented with X-Gal and different concentrations of H-CHG. Wild-type V583 with pPB101 (promoterless lacZ) was used as the negative control for all panels. (a) efrE promoter activity (pFL201) in wild-type V583 and the ΔchlR strain. (b) chlR promoter activity (pFL202) in wild-type V583 and the ΔchlR strain. (c) efrE promoter activity in wild-type V583 with (pFL204) or without (pFL203) mutation of the 3′ region of the putative ChlR binding motif. The images shown are representative of those from three independent trials.

β-Galactosidase assays. Cultures were spotted on BHI agar plates supplemented with X-Gal and different concentrations of H-CHG. Wild-type V583 with pPB101 (promoterless lacZ) was used as the negative control for all panels. (a) efrE promoter activity (pFL201) in wild-type V583 and the ΔchlR strain. (b) chlR promoter activity (pFL202) in wild-type V583 and the ΔchlR strain. (c) efrE promoter activity in wild-type V583 with (pFL204) or without (pFL203) mutation of the 3′ region of the putative ChlR binding motif. The images shown are representative of those from three independent trials. We constructed a chlR promoter reporter, pFL202 (Fig. 4b), to assess the responses of the P promoter to H-CHG. Unlike P, P was active regardless of the presence or absence of H-CHG. Moreover, P was active in V583 ΔchlR irrespective of the presence or absence of H-CHG (Fig. 6b). The P promoter includes a consensus −35 sequence (TTGACA) and a near-consensus −10 region (TACAAT) for binding by a housekeeping sigma factor. The −10 and −35 sequences are separated by 19 bp. This 19-bp spacing is typical for MerR family promoters; MerR regulators recruit RNA polymerase holoenzyme to nonoptimal promoters (18, 19). Unusually, however, the TSS of P occurs 13 bp downstream from the 3′ end of the −10 region. Nonstandard TSS spacing was also observed for the MerR regulation of merA in the archaeon Sulfolobus solfataricus (20) but to our knowledge has not been observed for other MerR regulators in bacteria. Typical MerR-regulated promoters harbor a palindromic MerR binding motif between the −35 and −10 promoter regions (18). Within the P promoter region, we identified a palindromic motif (underlined), TTCAAGTTACTTGAA (Fig. 5), which does not occur elsewhere on the V583 chromosome. Because the 5′ half of the motif lies directly adjacent to the predicted −35 region (Fig. 5), alteration of that sequence may prevent RNA polymerase binding. We modified the 3′ motif from ACTTGAA to CAGCTAC to determine if this motif affects efrEF promoter inducibility. H-CHG induction was abolished for the construct with the mutant P promoter (Fig. 6c).

DISCUSSION

In this study, we performed transcriptomic analysis to identify genes that are differentially regulated when E. faecalis V583 is exposed to H-CHG. The genes efrE and efrF were the most highly upregulated. We found that efrEF and the transcription regulator ChlR are required for the H-CHG stress response in E. faecalis V583. ChlR activates efrEF expression in response to H-CHG. These results are consistent with and identify new features of the chlorhexidine stress response in enterococci. The efrEF orthologs in a VanA-type VRE strain, E. faecium 1,231,410, were also upregulated in the presence of H-CHG (21). Moreover, sequential subinhibitory H-CHG exposure selected for E. faecium 1,231,410 efrE mutations that conferred reduced H-CHG susceptibility (22). Finally, deletion of efrE in E. faecalis OG1RF conferred decreased susceptibility to chlorhexidine and pentamidine (23, 24). Our results deepen our understanding of efrEF by identifying a transcriptional regulator that is required for the induction of efrEF expression in response to H-CHG stress. Gaps in knowledge about the enterococcal response to chlorhexidine stress remain. Specifically, what does EfrEF transport, and what ligand activates ChlR? These processes are significant because they reduce enterococcal susceptibility to chlorhexidine. Hassan et al. discovered chlorhexidine efflux proteins in Gram-negative bacteria (25, 26), but EfrEF does not belong to this protein family. Overexpression of efrEF in Lactococcus lactis conferred enhanced efflux of fluorescent dyes and decreased susceptibility to multiple antibiotics (12). Monitoring of [14C]chlorhexidine transport in E. faecalis wild-type and ΔefrEF strains would be required to determine whether chlorhexidine is a substrate for EfrEF. Alternatively, EfrEF may transport a metabolite that is required for the cell to survive the stress imposed by H-CHG and other antimicrobials. ChlR belongs to the MerR regulator family. MerR was first identified as a transcriptional activator of the mercury resistance (mer) operon in Gram-negative bacteria. An activated MerR dimer bound at a dyad symmetrical motif sequence in the mer promoter region drives a conformational change in DNA that results in induction of mer operon expression (18, 19). Generally, MerR family proteins possess two domains: a highly conserved N-terminal DNA binding region and a poorly conserved C-terminal ligand binding region (18, 19). The functionality of the N-terminal region depends on ligand binding by the C terminus. The variable C-terminal sequences of the MerR protein family recognize different ligands, including metals and dyes, and therefore lack amino acid sequence conservation (18, 19). The C-terminal region of ChlR possesses no predicted conserved domains. As shown by our microarray and β-galactosidase reporter analyses, chlR expression is not induced by H-CHG. It appears that ChlR requires H-CHG or metabolites associated with H-CHG stress to induce efrEF expression. Our study did not determine whether chlorhexidine directly interacts with ChlR. The observation that efrEF is upregulated in response to the plasmid postsegregational killing toxin Fst (27) confirms that efrEF upregulation is not specific to H-CHG stress. It is unknown whether ChlR mediates the Fst-dependent upregulation of efrEF. Identifying the specific ligand of ChlR will be a topic of future studies. In conclusion, our study provides novel insights into the transcriptomic response of vancomycin-resistant E. faecalis to chlorhexidine. The chlR and efrEF genes play key roles in E. faecalis survival of H-CHG exposure at concentrations near the MIC. Notably, 1/8× MIC H-CHG activated ChlR-dependent efrEF expression; induction at lower concentrations may occur, but we did not test this. In a hospital environment, E. faecalis is likely exposed to subinhibitory concentrations of H-CHG which are not lethal but are sufficient to elicit a transcriptional response. It remains to be determined whether this transcriptional response impacts susceptibility to other clinically relevant antimicrobials.

MATERIALS AND METHODS

Bacterial strains and routine molecular biology procedures.

The bacterial strains and plasmids used in this study are listed in Table 1. E. faecalis was routinely cultured in brain heart infusion (BHI) medium with or without agar at 37°C unless otherwise noted. Escherichia coli was routinely cultured in lysogeny broth or agar at 37°C unless otherwise noted. Chloramphenicol was used at 15 μg/ml. PCR was performed with Taq polymerase (New England BioLabs) or Phusion (Fisher Scientific). Plasmids were purified using a QIAprep Spin Miniprep kit (Qiagen). Inserts in engineered plasmids were sequenced (Massachusetts General Hospital DNA Core) to ensure that no mutations occurred during cloning. The sequences of the primers used in this study are provided in Table S1 in the supplemental material.
TABLE 1

Bacterial strains and plasmids used in this study

Strain or plasmidDescriptionReference or source
Bacterial strains
    E. faecalis strains
        V583Bloodstream isolate; VanB-type VRE13
        OG1RFHuman oral isolate33
        ΔchlRE. faecalis V583 ΔchlRThis study
        ΔefrEFE. faecalis V583 ΔefrEFThis study
        ΔefrEF/pFL103E. faecalis V583 ΔefrEF transformed with pFL103This study
        FL101E. faecalis V583 transformed with pPB101This study
        FL201E. faecalis V583 transformed with pFL201This study
        FL202E. faecalis V583 transformed with pFL202This study
        FL203E. faecalis V583 transformed with pFL203This study
        FL204E. faecalis V583 transformed with pFL204This study
        ΔchlR/pFL102ΔchlR mutant transformed with pFL102This study
        ΔchlR/pFL201ΔchlR mutant transformed with pFL201This study
        ΔchlR/pFL202ΔchlR mutant transformed with pFL202This study
    E. coli strains
        EC1000Cloning host; provides repA in trans; F araD139 (ara ABC-leu)7679 galU galK lacX74 rspL thi repA of pWV01 in glgB Km34
        DH5αCloning host; F endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 hsdR17(rK mK+) λ35
        BW23474Cloning host for pPB101 and derivatives; Δlac-169 robA1 cre C510 hsdR514 endA recA1 ΔuidA::pir-11636
Plasmids
    pHA101pLT06 plasmid with oriT from pHOU2 inserted at PstI21
    pCAT28Shuttle vector; pUC and pAMβ1 origins; confers chloramphenicol resistanceM. Rodrigues and K. Palmer
    pFL102pCAT28 containing 882-bp EcoRI/BamHI-digested chlR ORF and promoter regionThis study
    pFL103pCAT28 containing 3,673-bp EcoRI/BamHI-digested efrEF ORF and promoter regionThis study
    pPB101pTCV-lac-cat; expression vector for Gram-positive bacteria; confers kanamycin, erythromycin, and chloramphenicol resistance21
    pFL201pPB101 with 114-bp EcoRI/BamHI-digested efrEF promoter regionThis study
    pFL202pPB101 with 114-bp EcoRI/BamHI-digested chlR promoter regionThis study
    pFL203pPB101 with 98-bp EcoRI/BamHI-digested efrEF promoter regionThis study
    pFL204pPB101 with 98-bp EcoRI/BamHI-digested efrEF promoter region with modified motif CAGCTACThis study
Bacterial strains and plasmids used in this study

Susceptibility testing.

Unless otherwise noted, the CHG used in this study was commercially available Hibiclens (referred to here as H-CHG). The H-CHG MIC was determined in BHI broth using broth microdilution. The MIC was defined as the lowest concentration of H-CHG that inhibited visible cell growth. MIC values were independently confirmed using chlorhexidine digluconate (Sigma). For all experiments in this study, 1× MIC refers to the E. faecalis V583 H-CHG MIC determined by broth microdilution.

Growth kinetic assays with H-CHG.

E. faecalis V583 growth was monitored by recording the optical density of the cultures at 600 nm (OD600) using a spectrophotometer. An overnight culture was diluted to an OD600 of 0.01 in BHI broth and incubated at 37°C with agitation at 100 rpm. At mid-log phase (OD600, between 0.4 and 0.5), 25 ml of culture was split into flasks with prewarmed medium with or without H-CHG such that concentrations of 1× MIC and 1/2× MIC were attained or no H-CHG was present (control). Growth was then monitored at 15-min intervals for the first half hour and 30-min intervals for the subsequent 3 h.

Transcriptomic analysis.

Total RNA was extracted from the E. faecalis V583 cultures after 15 min exposure to 1× MIC H-CHG or no H-CHG. Briefly, 10 ml culture was transferred to 20 ml RNA Protect Bacteria reagent (Qiagen) and incubated at room temperature for 10 min. Cells were then pelleted by centrifugation at 11,000 × g, resuspended in IHB-1 buffer (50 mM glucose, 25 mM Tris, 10 mM EDTA, pH 8.0) supplemented with 125 μl of a 50-mg/ml lysozyme stock and 25 μl of a 2.5-kU/ml mutanolysin stock, and incubated at 37°C for 20 min. Total RNA was isolated by RNA Bee (Tel-Test) extraction following the manufacturer's protocol. RNA was dissolved in 50 μl RNase-free water (Ambion). RNA samples were treated with RNase-free DNase I (Roche) to remove contaminating DNA and purified using a Qiagen RNeasy kit. DNA contamination was monitored by PCR with primers targeting a 16S rRNA gene (Table S1). RNA integrity was confirmed by visualization of intact 23S and 16S rRNA bands on a 1% agarose gel. RNA was quantified with a NanoDrop spectrophotometer. cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) and random hexamers (Qiagen). Three micrograms of cDNA was fragmented with Roche DNase I and 3′ end labeled using a Bioarray terminal labeling kit (Enzo). Labeled, fragmented cDNA was hybridized to custom Affymetrix GeneChips probing the E. faecalis V583 gene sequences (Gilmorea520187F) (15). Processing of Affymetrix GeneChips was performed at the University of Iowa DNA facility. Two independent transcriptome experiments were performed.

Microarray data analysis.

Microarray data were processed by the bioconductor package based on the R statistical programming environment. The .cel files were preprocessed by use of the robust multiarray average (RMA) algorithm, and the processed data were subjected to gene expression analysis by the linear models for microarray data (Limma) package (28). All codes utilized for gene expression analysis followed the Limma user's guide. Statistical analysis was performed utilizing two independent microarray data sets. Genes with a fold change of ≥4 and a false discovery rate-adjusted P value of <0.05 were considered further.

Semiquantitative and quantitative RT-PCR.

Reverse transcriptase PCR (RT-PCR) was performed to confirm select microarray results and to determine whether efrE and efrF are cotranscribed. For semiquantitative RT-PCR, RNA (100 ng) was used as the template for cDNA synthesis with 250 ng random hexamers and SuperScript II reverse transcriptase (Invitrogen). Five nanograms of the resulting purified cDNA was used as the template for PCR. The housekeeping gene clpX was used as a control. Quantitative reverse transcriptase PCR (qRT-PCR) was performed with an AzuraQuant green fast quantitative PCR (qPCR) mix per the manufacturer's recommendations. qRT-PCR experiments were performed independently three times. The gyrB housekeeping gene was used as a control, and expression was normalized to the level of expression of this gene. Statistical significance was assessed by the Student t test.

Construction of deletion mutants.

Vector pHA101 (21), a derivative of pLT06 (29), was used to create deletion mutants of E. faecalis V583. Mutants were generated by markerless in-frame deletion as previously described (21). Briefly, ∼1.0-kb regions upstream and downstream of the gene(s) targeted for deletion were amplified by PCR. Products were digested by the restriction enzymes indicated in Table 1 and ligated with pHA101. Plasmid constructs were propagated in E. coli EC1000 with chloramphenicol selection. Plasmids were transformed into E. faecalis V583 cells by electroporation (30). Deletions were generated using temperature shift and p-chlorophenylalanine counterselection as previously described (21, 29).

Complementation of deletion mutants.

Deletion mutant strains were complemented in trans using the shuttle vector pCAT28, a derivative of pAT28 (31) that confers chloramphenicol resistance. For complementation, the chlR or efrEF complete ORFs with predicted promoter regions were amplified by PCR, treated with the restriction enzymes indicated in Table 1 and S1, and ligated into pCAT28. Plasmids were propagated in E. coli DH5α and electroporated into E. faecalis.

Primer extension.

Total RNA was obtained as described above. Primer extension was performed using 6-carboxyfluorescein-labeled primers as previously described (32). DNA fragment analysis was processed at the University of Oklahoma Health Sciences Center Laboratory for Genomics and Bioinformatics. Data were analyzed by Peak Scanner software (version 1.0; Thermo Fisher). The size of the most abundant cDNA product was used to determine the transcription start site.

Viability assay.

Broth cultures were adjusted to an OD600 of 0.3 and serially diluted in phosphate-buffered saline (PBS). Ten microliters of each dilution was spotted on agar plates containing different concentrations of H-CHG. Colonies were counted after overnight incubation at 37°C. Counts of colonies of between 20 and 200 were taken into consideration and normalized.

β-Galactosidase assay.

The putative promoter regions of the efrEF operon and the chlR gene were amplified using PCR. Products were digested by EcoRI and BamHI and ligated into pPB101 (21). pPB101 and derivatives were propagated in E. coli BW23474 and then transformed into E. faecalis strains by electroporation. For the β-galactosidase assay, a qualitative assay was used. Stationary-phase cultures were adjusted to an OD600 of 0.3 and diluted in PBS buffer. Ten microliters of each dilution was spotted on BHI agar plates supplemented with 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) and different concentrations of H-CHG.

Accession number(s).

The microarray data have been deposited in the EMBL-EBI data bank (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5181.
  34 in total

1.  Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis.

Authors:  I T Paulsen; L Banerjei; G S A Myers; K E Nelson; R Seshadri; T D Read; D E Fouts; J A Eisen; S R Gill; J F Heidelberg; H Tettelin; R J Dodson; L Umayam; L Brinkac; M Beanan; S Daugherty; R T DeBoy; S Durkin; J Kolonay; R Madupu; W Nelson; J Vamathevan; B Tran; J Upton; T Hansen; J Shetty; H Khouri; T Utterback; D Radune; K A Ketchum; B A Dougherty; C M Fraser
Journal:  Science       Date:  2003-03-28       Impact factor: 47.728

2.  Identifying cloned Helicobacter pylori promoters by primer extension using a FAM-labelled primer and GeneScan analysis.

Authors:  Amanda L Lloyd; Barry J Marshall; Brian J Mee
Journal:  J Microbiol Methods       Date:  2005-03       Impact factor: 2.363

3.  Two targets in pCF10 DNA for PrgX binding: their role in production of Qa and prgX mRNA and in regulation of pheromone-inducible conjugation.

Authors:  Taeok Bae; Briana Kozlowicz; Gary M Dunny
Journal:  J Mol Biol       Date:  2002-02-01       Impact factor: 5.469

4.  Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci.

Authors:  Michael O Vernon; Mary K Hayden; William E Trick; Robert A Hayes; Donald W Blom; Robert A Weinstein
Journal:  Arch Intern Med       Date:  2006-02-13

5.  Chlorhexidine Induces VanA-Type Vancomycin Resistance Genes in Enterococci.

Authors:  Pooja Bhardwaj; Elizabeth Ziegler; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  Differential actions of chlorhexidine on the cell wall of Bacillus subtilis and Escherichia coli.

Authors:  Hon-Yeung Cheung; Matthew Man-Kin Wong; Sau-Ha Cheung; Longman Yimin Liang; Yun-Wah Lam; Sung-Kay Chiu
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

7.  Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems.

Authors:  Karl A Hassan; Qi Liu; Peter J F Henderson; Ian T Paulsen
Journal:  mBio       Date:  2015-02-10       Impact factor: 7.867

Review 8.  Chlorhexidine bathing and health care-associated infections among adult intensive care patients: a systematic review and meta-analysis.

Authors:  Steven A Frost; Mari-Cris Alogso; Lauren Metcalfe; Joan M Lynch; Leanne Hunt; Ritesh Sanghavi; Evan Alexandrou; Kenneth M Hillman
Journal:  Crit Care       Date:  2016-11-23       Impact factor: 9.097

9.  Reduced Chlorhexidine and Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium after Serial Chlorhexidine Exposure.

Authors:  Pooja Bhardwaj; Amrita Hans; Kinnari Ruikar; Ziqiang Guan; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

10.  PSORTdb: expanding the bacteria and archaea protein subcellular localization database to better reflect diversity in cell envelope structures.

Authors:  Michael A Peabody; Matthew R Laird; Caitlyn Vlasschaert; Raymond Lo; Fiona S L Brinkman
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 16.971

View more
  6 in total

Review 1.  Adaptation to Adversity: the Intermingling of Stress Tolerance and Pathogenesis in Enterococci.

Authors:  Anthony O Gaca; José A Lemos
Journal:  Microbiol Mol Biol Rev       Date:  2019-07-17       Impact factor: 11.056

2.  Using Selection by Nonantibiotic Stressors to Sensitize Bacteria to Antibiotics.

Authors:  Jeff Maltas; Brian Krasnick; Kevin B Wood
Journal:  Mol Biol Evol       Date:  2020-05-01       Impact factor: 16.240

3.  Functional Synergy Of Antimicrobial Peptides And Chlorhexidine Acetate Against Gram-Negative/Gram-Positive Bacteria And A Fungus In Vitro And In Vivo.

Authors:  Jie Zhu; Yibing Huang; Mingxia Chen; Cuihua Hu; Yuxin Chen
Journal:  Infect Drug Resist       Date:  2019-10-15       Impact factor: 4.003

4.  The AdcACB/AdcAII system is essential for zinc homeostasis and an important contributor of Enterococcus faecalis virulence.

Authors:  Ling Ning Lam; Debra N Brunson; Jonathan J Molina; Ana L Flores-Mireles; José A Lemos
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

5.  Evolution of Chlorhexidine Susceptibility and of the EfrEF Operon among Enterococcus faecalis from Diverse Environments, Clones, and Time Spans.

Authors:  Ana P Pereira; Patrícia Antunes; Rob Willems; Jukka Corander; Teresa M Coque; Luísa Peixe; Ana R Freitas; Carla Novais
Journal:  Microbiol Spectr       Date:  2022-07-07

6.  SigV Mediates Lysozyme Resistance in Enterococcus faecalis via RsiV and PgdA.

Authors:  Srivatsan Parthasarathy; Xiaofei Wang; Kristen R Carr; Sriram Varahan; Elyssa B Hancock; Lynn E Hancock
Journal:  J Bacteriol       Date:  2021-08-09       Impact factor: 3.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.